Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $27.00.

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

(Reuters) -Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...